SFAS 123 (R) stock
option charges 196,446 158,770 867,089 635,946
expenses 57,119 49,345 163,883 144,725
expenses 209,862 25,210 632,865 78,323
loss $(465,870) $(819,643) $(1,459,799) $(3,258,411)
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder (OAB) symptoms. We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for certain forward-looking statements. This press release contains
forward-looking statements, which reflect our views regarding future events
and financial performance. These forward-looking statements are subject to
certain risks and uncertainties, including those identified below, which
could cause actual results to differ materially from historical results or
those anticipated. The words "aim," "believe," "expect," "anticipate,"
"intend," "estimate" and other expressions, which indicate future events
and trends, identify forward-looking statements. Actual future results and
trends may differ materially from historical results or those anticipated
depending upon a variety of factors, including, but not
|SOURCE Uroplasty, Inc.|
Copyright©2008 PR Newswire.
All rights reserved